UCART-123 is a Gene-Modified Cell Therapy owned by Cellectis, and is involved in 1 clinical trial, which is ongoing.

UCART-123 acts by targeting cells expressing CD123 antigen. CD123 is up-regulated in AML. CARs are comprised of an antigen-binding domain, an extracellular spacer/hinge region, a transmembrane domain and an intracellular signaling domain resulting in T cell activation after antigen binding. T cells are genetically modified with anti-CD123 CARs. These CAR T-cells binds to CD123 surface antigens and results in the cytotoxic T-lymphocyte (CTL) response against CD123 expressing malignant cells and thereby checks the progression of the disease condition.

The revenue for UCART-123 is expected to reach a total of $52m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the UCART-123 NPV Report.

UCART-123 is originated and owned by Cellectis.

UCART-123 Overview

UCART-123 is under development for the treatment of acute myeloid leukemia, Hodgkin lymphoma. It is administered through intravenous route. The therapeutic candidate acts by targeting CD123 antigen. It is developed based on CAR-T platform technology. It was also under development for the treatment of chronic myelocytic leukemia (CML), hairy cell leukemia (HCL), myelodysplastic syndrome (MDS), blastic plasmacytoid dendritic cell neoplasm and pediatric leukemias.

Cellectis Overview

Cellectis, operates as a clinical-stage biopharmaceutical company. It carries out research, develop and commercialize gene editing technology. The company pioneer’s gene editing company, deploying core proprietary technologies to develop off-the-shelf immunotherapies to target and eradicate cancer cells. It develops treatment based on allogeneic T-cell for the treatment of cancer. Cellectis therapeutic pipeline products include products for hematopoietic tumors includes UCART19, UCARTS1, UCART123, UCART22, UCART-BCMA and UCART38; and products for solid tumors including UCART5T4, UCART-EgfrVIII, s-3, s-4, s-5, s-6, and s-7. The company carries out research and development in the field of oncology and gene editing. It operates in New York and Paris. Cellectis is headquartered in Paris, France.

The company reported revenues of (US Dollars) US$67.1 million for the fiscal year ended December 2021 (FY2021), a decrease of 18.7% over FY2020. The operating loss of the company was US$130.7 million in FY2021, compared to an operating loss of US$85.4 million in FY2020. The net loss of the company was US$114.2 million in FY2021, compared to a net loss of US$81.1 million in FY2020. The company reported revenues of US$1.9 million for the third quarter ended September 2022, a decrease of 70.9% over the previous quarter.

Quick View – UCART-123

Report Segments
  • Innovator
Drug Name
  • UCART-123
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.